In patients with resected stage III mismatch repair-deficient colon cancer, adjuvant atezolizumab plus standard chemotherapy ...
Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen. Whether the addition of atezolizumab (an anti–programmed death ligand 1 agent) to a ...
The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...
Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data Patients with stage I-III colon cancer treated with upfront ...
The Dako Omnis test identifies mismatch repair deficient colorectal cancer patients eligible for Opdivo or Opdivo plus Yervoy treatment. Mismatch repair deficiency results in DNA replication errors, ...
Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...
The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...
Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results